There was no difference across study periods regarding pituitary adenoma size, the proportion of macroadenomas, IGF-I × ULN at diagnosis, or the proportion of patients achieving IGF-I control at 3–5 years or the latest follow-up in acromegaly patients with a cancer diagnosis. Here, IGF1 is linked to cancer.